电话:(86)731 84805380
传真:(86)731 82354476
地址:湖南长沙湘雅路110号,湘雅医学院北院原图书馆3楼
李明达博士1998年于多伦多大学获得遗传医学学士学位,2002年于剑桥大学获得病毒学博士学位。随后,他在杜克大学医学中心霍华德•休斯药检所从事艾滋病毒研究。2003年,他加入台湾中央研究院生物医学科学研究所陳垣崇院士课题组,从事博士后研究工作,并于2004年升任国家基因组药学中心副主任,2011年后担任台湾中央研究院生物医学科学研究所国家遗传药理学中心主任。
李明达博士从事罕见疾病遗传学、复杂疾病、遗传药理学等研究。参与了汉族人群第一个I型躁郁症GWAS研究。他的主要成就是“在进行华法林使用剂量的遗传药理学研究时,发现单核苷酸多态性与华法林剂量相关”。此外,他还参与了氯吡格雷反应、非甾体抗炎药引起的血管神经性水肿以及类固醇消炎药拉莫三嗪引起的史蒂文斯-约翰逊综合症等。他参与国际华法林遗传药理学联盟,国际氯吡格雷遗传药理学联盟,临床遗传药理学实施联盟等,并领导一支研究HLA-B*5801和别嘌呤醇临床应用的专业团队。
Dr. Ming Ta Michael Lee
Ming Ta Michael Lee graduated from the University of Toronto in 1998 with a B.Sc. degree in Medical Genetics. He then obtained his PhD in Virology from the University of Cambridge in 2002. Afterwards, he joined Dr. Bryan Cullen’s lab as a Research Associate at Howard Hughes Medical Institute at Duke University Medical Center working on HIV. He then joined Dr. Yuan-Tsong Chen’s (陳垣崇) lab as a postdoc at Institute of Biomedical Sciences, Academia Sinica in Sept 2003 and was promoted to assistant director at the National Center for Genome Medicine (NCGM) from April 2004 and serves as the Director of the Pharmacogenomic Center in 2011 at Institute of Biomedical Sciences, Academia Sinica.
Michael is involved in various genetic studies from rare diseases, complex diseases (osteoarthritis, bipolar disorder and schizophrenia) and Pharmacogenetics. He is involved in the first genome-wide association study on bipolar I disorder in the Han-Chinese population. His major achievement is in the phmarmacogenetic study of warfarin dose requirements, which he identified the SNP associated with warfarin dose. In addition to warfarin, he is also in involves in other pharmacogenetic studies such as clopidogrel response, NSAID induced angioedema, lamotrigine induced Stevens-Johnson Syndrome. He also actively participates in several major international consortium, such as International Warfarin Pharmacogenetic Consortium, International Clopidogrel Pharmacogenetic Consortium, Clinical Pharmacogenetics Implementation Consortium and leading a group of expert developing clinical use of HLA-B*5801 and allopurinol.